Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medco Founder Wygod Will Focus On Payor Relations At WebMD As Co-Ceo

  • News

Executive Summary

Medical Manager Chairman Martin Wygod will focus on the payor side of WebMD's business in his new role as co-CEO following a merger with Healtheon/WebMD.

You may also be interested in...



Merck-Medco Management Transition Complete: Clark Succeeds Lofberg

Merck-Medco will be headed by a veteran Merck executive as the PBM division moves to a new level of prominence within the pharmaceutical company parent.

Merck-Medco Management Transition Complete: Clark Succeeds Lofberg

Merck-Medco will be headed by a veteran Merck executive as the PBM division moves to a new level of prominence within the pharmaceutical company parent.

WebMD

Co-CEO Jeffrey Arnold resigns leaving Martin Wygod as CEO. Wygod took over as co-CEO in June following Healtheon/WebMD's acquisition of Medical Manager/CareInsite (1"The Pink Sheet" Jun. 26, p. 18)

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS036241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By